Utama › Sarkoma Ewing › Michigan
Kajian klinikal Sarkoma Ewing di Michigan
8 kajian untuk Sarkoma Ewing sedang mencari peserta di lokasi di Michigan.
Bandar di Michigan
Teks kajian rasmi (Bahasa Inggeris)
Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes
- Helen DeVos Children's Hospital, Grand Rapids
Mengambil pesertaFasa 1
Umur 1 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT07194044Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Corewell Health ( Site 1001), Grand Rapids
Mengambil pesertaFasa 1/2
6 Months – 25 Years · Semua jantina · Dikemas kini 17 Sep 2026 · NCT06395103Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
- University of Michigan, Ann Arbor
- START Midwest Michigan, PC, Grand Rapids
Mengambil pesertaFasa 1
Umur 12 hingga 85 · Semua jantina · Dikemas kini 8 Sep 2026 · NCT03715933Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
- Children's Hospital of Michigan/Wayne State University, Detroit
Mengambil pesertaFasa 1/2
Sehingga umur 30 · Semua jantina · Dikemas kini 3 Sep 2026 · NCT06541262Lurbinectedin in FET-Fused Tumors
- University of Michigan, Ann Arbor
Mengambil pesertaFasa 1/2
Umur 10 ke atas · Semua jantina · Dikemas kini 2 Sep 2026 · NCT05918640Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- C S Mott Children's Hospital, Ann Arbor
Mengambil pesertaFasa 1/2
12 Months – 30 Years · Semua jantina · Dikemas kini 25 Ogo 2026 · NCT04851119A Study to Evaluate the Utilization of 3D Printed Models in Pre-Operative Planning
- William Beaumont University Hospital, Royal Oak
Mengambil peserta
Umur 13 ke atas · Semua jantina · Dikemas kini 6 Feb 2026 · NCT06387485Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma
- Corewell Health, Grand Rapids
Mengambil pesertaFasa 1/2
Umur 2 hingga 30 · Semua jantina · Dikemas kini 3 Feb 2026 · NCT05734066Daripada ClinicalTrials.gov, data diperoleh pada 4 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.